BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36732923)

  • 1. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
    Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
    Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.
    Li PP; Li RG; Huang YQ; Lu JP; Zhang WJ; Wang ZY
    Aging (Albany NY); 2021 Nov; 13(21):24171-24191. PubMed ID: 34740994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
    Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
    Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA PRKCQ-AS1 promotes CRC cell proliferation and migration via modulating miR-1287-5p/YBX1 axis.
    Cui G; Zhao H; Li L
    J Cell Biochem; 2020 Oct; 121(10):4166-4175. PubMed ID: 32619070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.
    Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H
    Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.
    Leng W; Liu Q; Zhang S; Sun D; Guo Y
    Cancer Biol Ther; 2020 Nov; 21(11):1072-1080. PubMed ID: 33138677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
    Han C; Fu Y; Zeng N; Yin J; Li Q
    Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
    Qiao Y; Wang B; Yan Y; Niu L
    Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
    Lu Q; Chen W; Ji Y; Liu Y; Xue X
    Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
    [No Abstract]   [Full Text] [Related]  

  • 11. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
    Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.
    Zhu S; Sun J; Liu X; Shao H; Feng C; Wang Z; Zheng X; Wei S
    Mol Cell Biol; 2022 Jun; 42(6):e0018821. PubMed ID: 35499320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA SEMA3B-AS1 Inhibits miR-513c-5p to Regulate the Progression of Triple-negative Breast Cancer.
    Yu H; Wu Y; Huang J; Li S
    Anticancer Res; 2023 Dec; 43(12):5475-5484. PubMed ID: 38030196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway.
    Chen Y; Gao H; Li Y
    Mol Cell Endocrinol; 2020 Jan; 500():110634. PubMed ID: 31678422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin Affects Paclitaxel Sensitivity of Ovarian Cancer Cells Through Autophagy Mediated by Long Noncoding RNASNHG7/miR-3127-5p Axis.
    Yu Z; Wang Y; Wang B; Zhai J
    Cancer Biother Radiopharm; 2022 Nov; 37(9):792-801. PubMed ID: 32522016
    [No Abstract]   [Full Text] [Related]  

  • 17. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA SOX21-AS1 regulates the progression of triple-negative breast cancer through regulation of miR-520a-5p/ORMDL3 axis.
    Liu X; Song J; Kang Y; Wang Y; Chen A
    J Cell Biochem; 2020 Nov; 121(11):4601-4611. PubMed ID: 32277517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54.
    Liu B; Yao P; Xiao F; Guo J; Wu L; Yang Y
    J Transl Med; 2021 Aug; 19(1):333. PubMed ID: 34353336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA AFAP1-AS1 Knockdown Represses Cell Proliferation, Migration, and Induced Apoptosis in Breast Cancer by Downregulating
    Cai B; Wang X; Bu Q; Li P; Xue Q; Zhang J; Ding P; Sun D
    Cancer Biother Radiopharm; 2022 Oct; 37(8):662-672. PubMed ID: 32955920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.